bavtavirine + GS-1720 + GS-6212

This is a **combination drug** consisting of three investigational antiretroviral agents: bavtavirine, GS-1720, and GS-6212, being developed for **HIV-1 infection**. - **Bavtavirine** is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits HIV-1 reverse transcriptase, preventing the transcription of viral RNA into DNA[9]. - **GS-1720** is a long-acting, oral integrase strand transfer inhibitor (INSTI) that blocks HIV integrase activity, preventing viral DNA integration into the host genome. It is designed for once-weekly dosing and has shown robust antiretroviral efficacy and tolerability in early-phase clinical trials[4][6][10][14]. - **GS-6212** is an investigational agent; available data indicate its use in combination regimens for HIV-1, but its specific mechanism is not detailed in public sources for this combination. This combination aims to provide a **fully oral, once-weekly antiretroviral regimen** with potent multi-target HIV suppression for people living with HIV-1[1][3].